drugset

drugset / Trial / NCT00470509

Adalimumab in Severe and Acute Sciatica

NCT00470509 ↗

Phase 2 Completed 61 enrolled University Hospital, Geneva

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.

Timeline

Start: 2005-05
Primary completion: 2008-01
Completion: 2008-06

Publications

Genevay S, Viatte S, Finckh A, Zufferey P, Balague F, Gabay C. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Aug;62(8):2339-46. doi: 10.1002/art.27499.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	Subcutaneous

Indications